How to Get AndroGel in Arkansas: Prescriptions, Telehealth, and Pharmacies

What Is AndroGel and Why Arkansas Patients Request It

AndroGel is a hydroalcoholic topical testosterone gel approved by the FDA for adult males with primary or hypogonadotropic hypogonadism. Applied once daily to the shoulders, upper arms, or abdomen, it delivers a controlled testosterone dose through the skin. Arkansas patients request it most often after fatigue, low libido, or mood changes prompt a primary-care workup that reveals subnormal testosterone levels.

The FDA first approved AndroGel 1% in 2000 and AndroGel 1.62% in 2011 [1]. Both formulations carry a boxed warning about secondary exposure in women and children, so application site coverage and hand-washing after use are non-negotiable clinical instructions.

Testosterone deficiency is not a minor inconvenience. The T-Trials (N=788 men, aged 65 and older, mean baseline total testosterone 234 ng/dL) showed that testosterone therapy produced a mean increase of 83 points on the sexual activity scale (P<0.001) and improved bone density at the spine by 7.5% vs. 1% with placebo at 12 months [2]. Those findings inform how clinicians in Arkansas justify prescribing decisions to both patients and insurance reviewers.

The Endocrine Society's 2018 clinical practice guideline states: "We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their quality of life" [3]. That language anchors the diagnosis-to-treatment pathway Arkansas prescribers follow.

Diagnosing Hypogonadism Before Any Arkansas Prescriber Will Act

Diagnosis comes first. No licensed prescriber in Arkansas will write for AndroGel without documented biochemical hypogonadism, and insurers require the same evidence for prior authorization.

The Endocrine Society guideline defines hypogonadism as total testosterone below 300 ng/dL confirmed on two separate morning blood draws, collected before 10 a.m. when testosterone peaks [3]. A single low value is insufficient because testosterone is pulsatile, and assay variability between labs can run as high as 10 to 15 percent [4].

Required baseline labs in most Arkansas clinical protocols include:

• Total testosterone (two morning draws, at least one week apart)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Sex hormone-binding globulin (SHBG) when total testosterone is borderline
• CBC with differential (baseline hematocrit before exogenous androgen therapy)
• Comprehensive metabolic panel
• PSA (men 40 and older, per the 2018 Endocrine Society guideline) [3]
• Prolactin if LH is low (to screen for pituitary adenoma)

The American Urological Association's 2018 guideline on testosterone deficiency adds that free testosterone should be calculated or measured when SHBG is abnormal, since total testosterone can appear normal while bioavailable hormone is deficient [5]. That scenario is common in obese patients, who have elevated SHBG-binding capacity.

Obtaining these labs in Arkansas is straightforward. National chains such as Quest Diagnostics and Labcorp operate across Little Rock, Fayetteville, Fort Smith, and Jonesboro, and most telehealth platforms can issue lab orders to any Arkansas collection site. Results typically return within 48 to 72 hours.

Who Can Prescribe AndroGel in Arkansas

Arkansas law permits medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (APRN) with prescriptive authority, and physician assistants (PA) to prescribe Schedule III controlled substances, including testosterone gel. The prescriber must hold an active Arkansas DEA registration or a federally assigned DEA number valid in Arkansas [6].

APRNs in Arkansas practice under a collaborative practice agreement with a physician, but they may independently prescribe controlled substances once the collaborative relationship is established, per Arkansas Code Annotated § 17-87-310 [6]. PAs operate under a practice agreement as well, but their prescriptive authority for Schedule III substances is not separately restricted beyond those agreements.

Endocrinologists and urologists are the specialists most familiar with hypogonadism workups, but family medicine physicians diagnose and manage the condition regularly. In rural Arkansas counties, access to specialists can mean a 60 to 120-minute drive; telehealth eliminates that barrier.

Telehealth Prescribing of AndroGel in Arkansas

Arkansas explicitly permits telehealth prescribing of controlled substances when certain standards of care are met. Arkansas Code Annotated § 17-80-117 allows a prescriber to establish a patient-physician relationship via synchronous audio-visual technology, satisfying the in-person evaluation requirement that federal law historically required [7].

Following the end of the federal COVID-19 public health emergency, the DEA extended its telehealth prescribing flexibilities for controlled substances through a series of interim rules. As of the most recent extension (published in the Federal Register, May 2023), Schedule III testosterone prescriptions may be issued via telemedicine when the prescriber and patient conduct a live, two-way video visit and the prescriber is licensed in the patient's state of residence [8]. Arkansas state law aligns with that framework.

Practical steps for Arkansas residents seeking AndroGel via telehealth:

1. Choose a telehealth platform with Arkansas-licensed prescribers and an active Arkansas DEA registration.
2. Complete an intake form, including symptom history and prior testosterone levels if available.
3. Order baseline labs through the platform's affiliated lab network or upload existing results.
4. Attend a synchronous video visit (audio-only visits are insufficient for Schedule III substances under DEA interim rules).
5. Receive an electronic prescription routed to a preferred Arkansas pharmacy or a mail-order pharmacy licensed to ship to Arkansas.

Most platforms charge a consultation fee between $75 and $199 for an initial visit, separate from lab and pharmacy costs.

Filling an AndroGel Prescription at an Arkansas Pharmacy

Brand-name AndroGel is available at most major retail pharmacies in Arkansas, including Walgreens, CVS, Walmart Pharmacy, and regional chains such as USA Drug. Without insurance, brand AndroGel 1.62% (60-dose pump) carries a cash price of approximately $450 to $550 per month. GoodRx and manufacturer discount programs from AbbVie (the AbbVie myAbbVie Assist program for eligible patients) can reduce out-of-pocket costs significantly [9].

Generic testosterone gel 1% (50 mg/5 g packets or pump) is available from multiple manufacturers and typically costs $60 to $140 per month at Arkansas pharmacies with a GoodRx coupon. The generic delivers the same active ingredient, testosterone USP, in an equivalent vehicle, and the FDA's generic approval standard requires bioequivalence within an 80-to-125-percent confidence interval [10].

503A compounding pharmacies licensed in Arkansas can prepare testosterone gel in custom concentrations (commonly 2% or 5% in a Versabase or PLO gel) when a prescriber documents a clinical reason the commercially available product cannot serve the patient. Those reasons might include a skin reaction to the commercial gel's alcohol base, or a need for a concentration not available commercially [11]. The Arkansas State Board of Pharmacy maintains a public list of licensed compounding pharmacies at pharmacy.arkansas.gov.

Controlled-substance prescriptions in Arkansas are subject to the Arkansas Prescription Drug Monitoring Program (PMP), operated under Arkansas Code Annotated § 17-92-502. Every dispensing pharmacy must report Schedule III testosterone prescriptions to the PMP within one business day, and prescribers can query the database to check for concurrent controlled-substance prescriptions [12].

Prior Authorization for AndroGel Under Arkansas Medicaid and Commercial Plans

Arkansas Medicaid (Arkansas DHS, Division of Medical Services) covers testosterone gel for male hypogonadism under a limited prior authorization (PA) pathway. PA requirements generally include:

• Diagnosis of primary or secondary hypogonadism (ICD-10 E29.1 or E23.0)
• Documentation of two testosterone levels below 300 ng/dL
• Trial failure or contraindication to at least one lower-cost testosterone formulation (typically testosterone cypionate injection, which costs approximately $30 to $40 per month at Arkansas pharmacies)
• Prescriber attestation that the patient has received counseling on fertility and cardiovascular risk

The PA process for Arkansas Medicaid takes three to ten business days. Urgent PA determinations must be completed within 72 hours under federal Medicaid managed-care rules [13].

Commercial plans sold on the Arkansas Health Insurance Marketplace follow similar PA criteria, though some Blue Cross Blue Shield of Arkansas plans cover generic testosterone gel without a separate PA step when the diagnosis code is correct. Patients should request a pharmacy benefit predetermination before the first fill.

The HealthRX Arkansas TRT Access Framework organizes the decision pathway into three tiers:

Tier 1 (No PA needed): Cash-pay patient using generic testosterone gel 1% at retail pharmacy. Time from prescription to fill: same day.

Tier 2 (PA likely required): Commercial insurance or Arkansas Medicaid patient requesting brand AndroGel. Time from prescription to approval: 3 to 10 days. Required documents: two testosterone lab results, ICD-10 code, prescriber notes, and prior formulation trial record.

Tier 3 (503A compounding route): Patient with documented sensitivity to commercial gel base or need for custom concentration. Prescriber writes a non-commercially-available justification letter. 503A Arkansas pharmacy compounds and ships within 5 to 7 business days.

Monitoring After Starting AndroGel in Arkansas

Prescribers do not simply write the prescription and disappear. Follow-up labs and clinical review are required by the Endocrine Society guideline at three to six months after initiation, then annually once stable [3].

At the three-month check, the standard panel includes:

• Total testosterone (drawn three to twelve hours after gel application to capture peak-to-trough values)
• Hematocrit (erythrocytosis risk increases with testosterone therapy; the Endocrine Society recommends withholding or reducing dose if hematocrit exceeds 54%) [3]
• PSA (for men 40 and older; a rise of more than 1.4 ng/mL in any 12-month period warrants urology referral) [3]
• Blood pressure and symptom review

A 2016 Cochrane systematic review of testosterone therapy trials (44 randomized controlled trials, N=9,849) found that testosterone significantly increased hematocrit (mean difference 3.18%, 95% CI 2.05 to 4.30%) relative to placebo, confirming the clinical rationale for CBC monitoring [14]. Erythrocytosis occurs less often with gel than with injectable testosterone because gel produces steadier serum levels without the supraphysiologic peaks seen after intramuscular injection [15].

If a patient applying AndroGel 5 g daily (50 mg testosterone) does not achieve a trough testosterone above 300 ng/dL at three months, the prescriber may increase to 7.5 g (the 1% formulation) or step up to the 1.62% pump, which delivers 40.5 mg per actuation and allows finer dose titration [1].

Transferring an Existing AndroGel Prescription to Arkansas

Patients relocating to Arkansas from another state can transfer their AndroGel prescription under certain conditions. Because testosterone gel is a Schedule III controlled substance, federal law and Arkansas regulations both apply.

Under the Controlled Substances Act, Schedule III prescriptions may be transferred between pharmacies once (or multiple times between pharmacies sharing a real-time electronic database) [16]. The receiving Arkansas pharmacy must verify the transferring pharmacy's DEA registration and confirm the prescription has not been partially or fully dispensed beyond the legal limit.

More commonly, patients who move to Arkansas need a new prescription from an Arkansas-licensed prescriber rather than a simple transfer, because many out-of-state prescribers are not licensed in Arkansas and cannot legally write ongoing controlled-substance prescriptions for Arkansas residents under the DEA's state-licensure rules. A telehealth visit with an Arkansas-licensed prescriber, using existing lab results from within the past six months, can produce a new prescription in one to three days.

Cardiovascular Considerations Arkansas Clinicians Review Before Prescribing

The FDA added a label warning in 2015 noting a possible increased risk of cardiovascular events with testosterone products, based on a 2010 trial (Basaria et al., N=209) that was stopped early due to excess cardiovascular events in the testosterone arm [17]. That finding prompted a large, definitive outcomes trial: TRAVERSE (N=5,246 hypogonadal men, aged 45 to 80 with pre-existing or high risk for cardiovascular disease), published in the New England Journal of Medicine in 2023. TRAVERSE showed non-inferiority of testosterone gel to placebo for major adverse cardiovascular events (MACE) at a median follow-up of 33 months (hazard ratio 0.96 to 95% CI 0.78 to 1.17) [18].

The FDA updated the testosterone label in 2024 to reflect the TRAVERSE findings, removing language suggesting a definitive cardiovascular risk increase while retaining the caution for patients with known serious cardiovascular disease [1]. Arkansas prescribers should review the updated label when counseling patients with coronary artery disease or prior myocardial infarction.

The American Heart Association notes that cardiovascular risk factor control, including blood pressure, lipid management, and weight reduction, remains essential in hypogonadal men considering testosterone therapy, regardless of TRAVERSE's reassuring primary endpoint [19].

How Long Until an Arkansas Patient Receives AndroGel

The fastest route is a cash-pay patient with recent qualifying labs and a telehealth visit: prescription issued on day one, filled at a local Arkansas retail pharmacy the same day or next day. Total time: one to two days.

For patients without existing labs, the timeline extends. Lab draw on day one, results in 48 to 72 hours, telehealth visit on day four, prescription issued, filled within one to two days. Total: five to seven days.

When prior authorization is needed, add three to ten business days for commercial insurance or Arkansas Medicaid review. A complete, well-documented PA submission, including both testosterone values, ICD-10 code, and prescriber notes, resolves faster than an incomplete one. Peer-to-peer review requests (prescriber calls the insurance plan's medical director) can accelerate denials to approvals within 24 to 48 hours.

503A compounding orders add compounding and shipping time. Arkansas-licensed 503A pharmacies typically compound and ship within five to seven business days. Some offer overnight shipping for an additional fee.

The realistic median time from first telehealth contact to gel in hand for an Arkansas resident is seven to fourteen days, assuming no PA complications.

Safety Profile and Contraindications Arkansas Prescribers Screen For

AndroGel is contraindicated in men with known or suspected prostate carcinoma or breast carcinoma, per the FDA label [1]. Absolute contraindications also include women who are or may become pregnant (secondary transfer risk), and patients with severe untreated sleep apnea (testosterone can worsen upper airway obstruction) [3].

Relative contraindications requiring careful discussion include:

• Hematocrit above 50% at baseline (increased erythrocytosis risk)
• Severe lower urinary tract symptoms (AUASI score above 19)
• Uncontrolled heart failure
• Desire for fertility preservation (testosterone suppresses LH and FSH, reducing intratesticular testosterone and spermatogenesis; men who want children should discuss alternatives such as clomiphene citrate or human chorionic gonadotropin before starting AndroGel) [3]

The skin transfer risk is real. Studies show that female partners exposed to application sites in gel-using men had measurable serum testosterone elevations within 24 hours of skin contact [1]. Patients must be instructed to cover application sites with clothing after the gel dries (typically 3 to 5 minutes) and to wash hands immediately after application.